Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: Studies comparing the cloned human noradrenaline and human dopamine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1437-1443

  Pifl, Christian ^a   Hornykiewicz, Oleh ^a   Giros, Bruno ^b,c   Caron, Marc G ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARRIER PROTEIN; CATECHOLAMINE; DESIPRAMINE; DOPAMINE; DRUG METABOLITE; NORADRENALIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DOPAMINE UPTAKE; DRUG UPTAKE; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; TRANSPORT KINETICS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; DESIPRAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS;

EID: 0030425447     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BUCK, K. J. AND AMARA, S. G.: Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. U.S.A. 91: 12584-12588, 1994.
2. BURNS, R. S., CHIUEH, C. C., MARKEY, S. P., EBERT, M. H., JACOBOWITZ, D. M. AND KOPIN, I. J.: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80: 4546-4550, 1983.
3. CHIBA, K., TREVOR, A. AND CASTAGNOLI, N., JR.: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574-578, 1984.
4. CULLEN, B. R.: Use of eucaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 152: 684-704, 1987.
5. DAVIS, G. C., WILLIAMS, A. C., MARKEY, S. P., EBERT, M. H., CAINE, E. D., REICHEST, C. M. AND KOPIN, I. J.: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1: 249-254, 1979.
6. DIPAOLO, T., BEDARD, P., DAIGLE, M. AND BOUCHER, R.: Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain Res. 379: 286-293, 1986.
7. GIROS, B., EL MESTIKAWY, S., GODINOT, N., ZHENG, K., HAN, H., YANG-FEN, T. AND CARON, M. G.: Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42: 383-390, 1992.
8. GU, H., WALL, S. C. AND RUDNICK, G.: Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269: 7124-7130, 1994.
9. HEIKKILA, R. E., MANZINO, L., CABBAT, F. S. AND DUVOISIN, R. C.: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (Lond.) 311: 467-469, 1984.
10. JAVITCH, J. A., D'AMATO, R. J., STRITTMATTER, S. M. AND SNYDER, S. H.: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82: 2173-2177, 1985.
11. JAVITCH, J. A. AND SNYDER, S. H.: Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106: 455-456, 1984.
12. JENNER, P., RUPNIAK, N. M. J., ROSE, S., KELLY, E., KILPATRICK, G., LEES, A. AND MARSDEN, C. D.: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50: 85-90, 1984.
13. JOHANNESSEN, J. N., CHIUEH, C. C., BURNS, R. S. AND MARKEY, S. P.: Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36: 219-224, 1985.
14. KILTY, J. E., LORANG, D. AND AMARA, S. G.: Cloning and expression of a cocaine-sensitive dopamine transporter. Science (Wash. DC) 254: 578-579, 1991.
15. KINEMUCHI, H., FOWLER, C. J. AND TIPTON, K. F.: The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydopyridine (MPTP) and its relevance to Parkinson's disease. Neurochem. Int. 11: 359-373, 1987.
16. LANGSTON, J. W., BALLARD, P., TETRUD, J. W. AND IRWIN, I.: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science (Wash. DC) 219: 979-978, 1983.
17. LANGSTON, J. W., FORNO, L. S., REBERT, C. S. AND IRWIN, I.: Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292: 390-394, 1984a.
18. LANGSTON, J. W., IRWIN, I., LANGSTON, E. B. AND FORNO, L. S.: Pargyline prevents MPTP-induced parkinsonism in primates. Science (Wash. DC) 225: 1480-1482, 1984b.
19. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol. Pharmacol. 36: 518-524, 1989.
20. MARKEY, S. P., JOHANNESSEN, J. N., CHIUEH, C. C., BURNS, R. S. AND HERKENHAM, M. A.: Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature (Lond.) 311: 464-467, 1984.
21. MCPHERSON, G. A.: Analysis of radioligand binding experiments: A collection of computer programs for the IBM PC. J. Pharmacol. Methods 14: 213-228, 1985.
22. MELAMED, E., ROSENTHAL, J., COHEN, O., GLOBUS, M. AND UZZAN, A.: Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur. J. Pharmacol. 116: 179-181, 1985.
23. MITCHELL, I. J., CROSS, A. J., SAMBROOK, M. A. AND CROSSMAN, A. R.: Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydopyridine in the Macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61: 195-200, 1985.
24. MOORE, R. Y. AND BLOOM, F. E.: Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Annu. Rev. Neurosci. 1: 129-169, 1978.
25. MOORE, R. Y. AND BLOOM, F. E.: Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2: 113-168, 1979.
26. PACHOLCZYK, T., BLAKELY, R. D. AND AMARA, S. G.: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature (Lond.) 350: 350-354, 1991.
27. PIFL, C., GIROS, B. AND CARON, M. G.: Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-pyridinium. J. Neurosci. 13: 4246-4253, 1993.
28. PIFL, CH., SCHINGNITZ, G. AND HORNYKIEWICZ, O.: Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44: 591-605, 1991.
29. SALACH, J. I., SINGER, T. P., CASTAGNOLI, N., JR. AND TREVOR, A.: Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun. 125: 831-835, 1984.
30. SCHULTZ, W., SCARNATI, E., SUNDSTRÖM, E., TSUISUMI, T. AND JONSSON, G.: The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. Exp. Brain Res. 63: 216-220, 1986.
31. SCHULTZ, W., STUDER, A., JONSSON, G., SUNDSTRÖM, E. AND MEFFORD, I.: Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neurosci. Lett. 59: 225-232, 1985.
32. +. FEBS Lett. 189: 225-230, 1985.
33. 3H]Nisoxetine: A new radioligand for norepinephrine uptake sites in brain. Eur. J. Pharmacol. 191: 239-243, 1990.
34. TIPTON, K. F. AND SINGER, T. P.: Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61: 1191-1206, 1993.